(I'm not a professional, and I have no background in ... anything! Read this at your own discretion)
Oh man, I've been seeing a ton of buzz about the booming progress of a reopened Las Vegas. Everyone's all, "Oh man, buy MGM and Caesars!" but I'm convinced that folks smarter than me have already done that- so the amazing strides the city has made in the last 3-6 months are likely priced in.
... Unless you know where to look.
There's a lot of background to absorb with regard to Flower One's operations over the past two years, and I'm far too uneducated to explore it with any depth. My understanding is that some of their licensing deals were less-than-advantageous, and I'm aware of a transaction that fell through with Subversive Capital; I'm also guessing that their revenue estimates were a little too lofty, and the higher-than-expected previous cost of biological assets ate into the company's ability to operate profitably. Oops!
Oh, and historically, their products had left a lot to be desired. I know what you're thinking: "consumers don't matter! it's stonks!!" Bro, I'm not paying $60 for weed that's bad on purpose. Nobody is. Was anybody really surprised when the Old Pal eighths weren't selling for $60? It was supposed to be a budget brand!
This is a turnaround story; how we got here is important to note. Now let's talk about how it's going...
Quality of products are way up. I'm saying this from an individual consumer perspective, but it's also evident in various social feeds. Folks used to frequently pile on the criticism about the quality of Flower One products, but in the last six months, that derision has turned into surprise almost across the board. There are a few vocal detractors who won't be won over without the "best, terp-fueled top shelf exclusive flower (45%THC!!)," but I'm betting that the majority of people will soon come to accept Flower One as a legitimately successful cultivator. +Bonus points for also being the largest in the state.
Oh, sorry- I haven't mentioned that yet! Hey, take a minute over on Headset and tell me who is sitting comfortably with five or six spots in the top-selling flower category (for Nevada). Is it still $floof with the top three? They've held these spots for months in addition to top sellers in the vape cartridge category. I'm not a mathematician, but I get the feeling that they've sold a vast amount of marijuana products. It should be noted: the SKUs represented in Headset sales barely scratch the ramped-up production from the last three months. There are hundreds of additional products that I know for a fact are selling like fire. While it's true that they're paying licensing fees (I'm guessing!) to grow and sell the top-end products, I'm thinking that the sheer volume offsets any disadvantages attached to branded products.
There's still a lot of risk here considering the delayed financials and the current debt load, but I'm personally waving off those concerns as necessary FUD. Heck, the "financial disclosure delay" situation is at least somewhat understandable considering the huge amount of work done restructuring the company's debt- the same auditor had a few other delays amongst other small cap marijuana companies, so I've got hope that it will all be appropriately sorted out in the coming days. Part of the restructuring deal was offering vendors equity, if I'm not mistaken- wouldn't they now have a vested interest in the success of the company? Personally, I'd think so.
Anyway, I don't really know what I'm talking about. I'm not sorry if you've read this far- that's 100% on you. I've got a tiny baby cash account, so my positions and opinion don't matter.
Oh man, I've been seeing a ton of buzz about the booming progress of a reopened Las Vegas. Everyone's all, "Oh man, buy MGM and Caesars!" but I'm convinced that folks smarter than me have already done that- so the amazing strides the city has made in the last 3-6 months are likely priced in.
... Unless you know where to look.
There's a lot of background to absorb with regard to Flower One's operations over the past two years, and I'm far too uneducated to explore it with any depth. My understanding is that some of their licensing deals were less-than-advantageous, and I'm aware of a transaction that fell through with Subversive Capital; I'm also guessing that their revenue estimates were a little too lofty, and the higher-than-expected previous cost of biological assets ate into the company's ability to operate profitably. Oops!
Oh, and historically, their products had left a lot to be desired. I know what you're thinking: "consumers don't matter! it's stonks!!" Bro, I'm not paying $60 for weed that's bad on purpose. Nobody is. Was anybody really surprised when the Old Pal eighths weren't selling for $60? It was supposed to be a budget brand!
This is a turnaround story; how we got here is important to note. Now let's talk about how it's going...
Quality of products are way up. I'm saying this from an individual consumer perspective, but it's also evident in various social feeds. Folks used to frequently pile on the criticism about the quality of Flower One products, but in the last six months, that derision has turned into surprise almost across the board. There are a few vocal detractors who won't be won over without the "best, terp-fueled top shelf exclusive flower (45%THC!!)," but I'm betting that the majority of people will soon come to accept Flower One as a legitimately successful cultivator. +Bonus points for also being the largest in the state.
Oh, sorry- I haven't mentioned that yet! Hey, take a minute over on Headset and tell me who is sitting comfortably with five or six spots in the top-selling flower category (for Nevada). Is it still $floof with the top three? They've held these spots for months in addition to top sellers in the vape cartridge category. I'm not a mathematician, but I get the feeling that they've sold a vast amount of marijuana products. It should be noted: the SKUs represented in Headset sales barely scratch the ramped-up production from the last three months. There are hundreds of additional products that I know for a fact are selling like fire. While it's true that they're paying licensing fees (I'm guessing!) to grow and sell the top-end products, I'm thinking that the sheer volume offsets any disadvantages attached to branded products.
There's still a lot of risk here considering the delayed financials and the current debt load, but I'm personally waving off those concerns as necessary FUD. Heck, the "financial disclosure delay" situation is at least somewhat understandable considering the huge amount of work done restructuring the company's debt- the same auditor had a few other delays amongst other small cap marijuana companies, so I've got hope that it will all be appropriately sorted out in the coming days. Part of the restructuring deal was offering vendors equity, if I'm not mistaken- wouldn't they now have a vested interest in the success of the company? Personally, I'd think so.
Anyway, I don't really know what I'm talking about. I'm not sorry if you've read this far- that's 100% on you. I've got a tiny baby cash account, so my positions and opinion don't matter.